Results 111 to 120 of about 762 (132)

Comparison of oliceridine and sufentanil in postoperative pain management for postoperative nausea and vomiting after bimaxillary orthognathic surgery: an exploratory randomized controlled trial. [PDF]

Front Med (Lausanne)
Zhou Y, Xiong G, Wang L, Liu Y, Wang X, Yang X.   +5 more
europepmc   +1 more source

Statistical Issues in the Oliceridine versus Sufentanil Trial for Elderly Thoracoscopic Surgery [Response to Letter]. [PDF]

Drug Des Devel Ther
Cai Y, Jiang Y, Wang Z, Sun H.
europepmc   +1 more source

Beyond Opioid Comparison: Interpreting Oliceridine in Contemporary Thoracic Recovery Pathways [Letter]. [PDF]

Drug Des Devel Ther
Lu CW, Chang KC.
europepmc   +1 more source

EC₅₀ of Remifentanil for Inhibiting Cardiovascular Responses to Tracheal Intubation in Patients Treated by Different Doses of Oliceridine: A Randomized Controlled Trial Using Up-and-Down Sequential Allocation Methodology. [PDF]

Drug Des Devel Ther
Zhao Z, Ge L, Wang X, Wang X, Huang J, Xiao Y, Zhang Y, Zhou Y, Bao R, Wang JF.   +9 more
europepmc   +1 more source

Oliceridine versus Sufentanil for Postoperative Recovery and Opioid-Related Adverse Events in Patients Undergoing Thoracoscopic Lobectomy: A Randomized Double-Blind Controlled Trial. [PDF]

Drug Des Devel Ther
Hu N, Wang C, Zhang QQ, Zhang ZJ, Ding X, Zhang Y.   +5 more
europepmc   +1 more source

Pharmacological Advances in Opioid Therapy: A Review of the Role of Oliceridine in Pain Management [PDF]

Pain and Therapy, 2021
Problems with the treatment of acute pain may arise when a patient is opioid-tolerant, such as those on chronic therapy with opioids or opiate replacement therapy, those who misuse opioids, and those who are in recovery. While some of the adverse effects
Amber Edinoff, Richard Urman, Alan Kaye   +2 more
exaly   +2 more sources

Budget impact and pharmacy costs with targeted use of oliceridine for postsurgical pain in patients at high risk of opioid-related adverse events

Expert Review of Pharmacoeconomics and Outcomes Research, 2022
Oliceridine, a new class of μ-opioid receptor agonist, may be associated with fewer opioid-related adverse events (ORAEs) due to its unique mechanism of action.
Kit Simpson, Michael Fossler, Linda Wase   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Further investigation of the rapid-onset and short-duration action of the G protein-biased μ-ligand oliceridine

Biochemical and Biophysical Research Communications, 2021
Kazuyuki Sugita, Tomohisa Mori, Yoshinori Takemura   +2 more
exaly  

Oliceridine for the Management of Acute Postoperative Pain

Annals of Pharmacotherapy, 2021
Junyi Yang
exaly  

Preclinical discovery and development of oliceridine (Olinvyk®) for the treatment of post-operative pain

Expert Opinion on Drug Discovery, 2022
David Lambert
exaly